The molecular biology of kidney cancer and its clinical translation into treatment strategies

Renal Cell Carcinoma: Molecular Targets and Clinical Applications

Volumn , Issue , 2009, Pages 79-97

  Kaelin Jr , William G ^a   George, Daniel J ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

Angiogenesis; HIF; Hypoxia; KDR; mTOR; VEGF; von Hippel Lindau

Indexed keywords

EID: 84863997735     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-59745-332-5_5     Document Type: Chapter

References (128)

1. Maher, E. and W. G. Kaelin, von Hippel-Lindau disease. Medicine, 1997. 76: pp. 381-91.
2. Kaelin, W. G., Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer, 2002. 2(9): pp. 673-82.
3. Stolle, C., et al., Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat, 1998. 12: pp. 417-23.
4. Zbar, B., et al., Germline mutations in the von Hippel-Lindau (VHL) gene in families from North America, Europe, and Japan. Human Mutat, 1996. 8: pp. 348-57.
5. Kim, W. Y. and W. G. Kaelin, Role of VHL gene mutation in human cancer. J Clin Oncol, 2004. 22(24): pp. 4991-5004.
6. Gnarra, J. R., et al., Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal cell carcinoma (review). Biochim Biophys Acta, 1996. 1242: pp. 201-10.
7. Maher, E. R. and C. Eng, The pressure rises: update on the genetics of phaeochromocytoma. Hum Mol Genet, 2002. 11(20): pp. 2347-54.
8. Lee, S., et al., Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell, 2005. 8(2): pp. 155-67.
9. Zhuang, Z., et al., von Hippel-Lindau disease gene deletion detected in microdissected sporadic human colon carcinoma specimens. Hum Pathol, 1996. 27(2): pp. 152-6.
10. Kuwai, T., et al., Mutation of the von Hippel-Lindau (VHL) gene in human colorectal carcinoma: association with cytoplasmic accumulation of hypoxia-inducible factor (HIF)-1alpha. Cancer Sci, 2004. 95(2): pp. 149-53.
11. Giles, R. H., et al., Interplay between VHL/HIF1alpha and Wnt/beta-catenin pathways during colorectal tumorigenesis. Oncogene, 2006. 25 (21) pp. 3065-70.
12. Iliopoulos, O., et al., Tumor suppression by the human von Hippel-Lindau gene product. Nat Med, 1995. 1(8): pp. 822-6.
13. Blankenship, C., et al., Alternate choice of initiation codon produces a biologically active product of the von Hippel-Lindau gene with tumor suppressor activity. Oncogene, 1999. 18: pp. 1529-35.
14. Schoenfeld, A., E. Davidowitz, and R. Burk, A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. Proc Natl Acad Sci USA 1, 1998. 95: pp. 8817-22.
15. Iliopoulos, O., M. Ohh, and W. Kaelin, pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc Natl Acad Sci USA, 1998. 95: pp. 11661-6.
16. Corless, C. L., et al., Immunostaining of the von Hippel-Lindau gene product (pVHL) in normal and neoplastic human tissues. Hum Pathol, 1997. 28: pp. 459-64.
17. Los, M., et al., Expression pattern of the von Hippel-Lindau protein in human tissues. Lab Investig, 1996. 75: pp. 231-8.
18. Ye, Y., et al., Subcellular localization of the von Hippel-Lindau disease gene product is cell cycle-dependent. Int J Cancer, 1998. 78: pp. 62-9.
19. Lee, S., et al., Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density. Proc Natl Acad Sci USA, 1996. 93: pp. 1770-5.
20. Lee, S., et al., Transcription-dependent nuclear-cytoplasmic trafficking is required for the function of the von Hippel-Lindau tumor suppressor protein. Mol Cell Biol, 1999. 19(2): pp. 1486-97.
21. Shiao, Y. H., et al., The von Hippel-Lindau tumor suppressor targets to mitochondria. Cancer Res, 2000. 60(11): pp. 2816-9.
22. Schoenfeld, A., E. Davidowitz, and R. Burk, Endoplasmic reticulum/cytosolic localization of von Hippel-Lindau gene products is mediated by a 64-amino acid region. Int J Cancer, 2001. 91: pp. 457-67.
23. Mekhail, K., et al., HIF activation by pH-dependent nucleolar sequestration of VHL. Nat Cell Biol, 2004. 6(7): pp. 642-7.
24. Mekhail, K., et al., Regulation of ubiquitin ligase dynamics by the nucleolus. J Cell Biol, 2005. 170(5): pp. 733-44.
25. Baba, M., et al., Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor. Oncogene, 2003. 22(18): pp. 2728-38.
26. Stebbins, C. E., W. G. Kaelin, and N. P. Pavletich, Structure of the VHL-ElonginC-elonginB complex: implications for VHL tumor suppressor function. Science, 1999. 284: pp. 455-61.
27. Ohh, M., et al., Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein. J Clin Investig, 1999. 104: pp. 1583-91.
28. Ohh, M., et al., Ubiquitination of HIF requires direct binding to the von Hippel-Lindau protein beta domain. Nat Cell Biol, 2000. 2: pp. 423-7.
29. Schofield, C. J. and P. J. Ratcliffe, Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol, 2004. 5(5): pp. 343-54.
30. Kaelin, W. G., Proline hydroxylation and gene expression. Annu Rev Biochem, 2005. 74: pp. 115-28.
31. Berra, E., et al., HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J, 2003. 22(16): pp. 4082-90.
32. Gerald, D., et al., JunD reduces tumor angiogenesis by protecting cells from oxidative stress. Cell, 2004. 118(6): pp. 781-94.
33. Kaelin, W. G., Jr., ROS: really involved in oxygen sensing. Cell Metab, 2005. 1(6): pp. 357-8.
34. Wang, V., et al., Differential gene up-regulation by hypoxia-inducible factor-1alpha and hypoxia-inducible factor-2alpha in HEK293T cells. Cancer Res, 2005. 65(8): pp. 3299-306.
35. Hu, C. J., et al., Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol, 2003. 23(24): pp. 9361-74.
36. Sowter, H. M., et al., Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer Res, 2003. 63(19): pp. 6130-4.
37. Jiang, Y., et al., Gene expression profiling in a renal cell carcinoma cell line: dissecting VHL and hypoxia-dependent pathways. Mol Cancer Res, 2003. 1(6): pp. 453-62.
38. Zatyka, M., et al., Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Cancer Res, 2002. 62(13): pp. 3803-11.
39. Czyzyk-Krzeska, M. F. and J. Meller, von Hippel-Lindau tumor suppressor: not only HIF's executioner. Trends Mol Med, 2004. 10(4): pp. 146-9.
40. Kaelin, W. G., Jr., The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing. Biochem Biophys Res Commun, 2005. 338(1): pp. 627-38.
41. Bishop, T., et al., Genetic analysis of pathways regulated by the von Hippel-Lindau tumor suppressor in Caenorhabditis elegans. PLoS Biol, 2004. 2(10): pp. e289.
42. Kurban, G., et al., Characterization of a von Hippel-Lindau pathway involved in extracellular matrix remodeling, cell invasion, and angiogenesis. Cancer Res, 2006. 66(3): pp. 1313-9.
43. Hoffman, M., et al., von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet, 2001. 10: pp. 1019-27.
44. Koochekpour, S., et al., The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol Cell Biol 1999. 19: pp. 5902-12.
45. Petrella, B. L., J. Lohi, and C. E. Brinckerhoff, Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma. Oncogene, 2005. 24(6): pp. 1043-52.
46. Stickle, N. H., et al., pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development. Mol Cell Biol, 2004. 24(8): pp. 3251-61.
47. Davidowitz, E., A. Schoenfeld, and R. Burk, aVHL induces renal cell differentiation and growth arrest through integration of cell-cell and cell-extracellular matrix signaling. Mol Cell Biol, 2001. 21: pp. 865-74.
48. Los, M., et al., Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene. Cancer Res, 1999. 59(17): pp. 4440-5.
49. Ohh, M., et al., The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell, 1998. 1: pp. 959-68.
50. Gnarra, J. R., et al., Post-transcriptional regulation of vascular endothelial growth factor mRNA by the VHL tumor suppressor gene product. Proc Natl Acad Sci USA, 1996. 93: pp. 10589-94.
51. Iliopoulos, O., et al., Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA, 1996. 93: pp. 10595-9.
52. Galban, S., et al., Influence of the RNA-binding protein HuR in pVHL-regulated p53 expression in renal carcinoma cells. Mol Cell Biol, 2003. 23(20): pp. 7083-95.
53. Datta, K., et al., Role of elongin-binding domain of von Hippel-Lindau gene product on HuR-mediated VPF/VEGF mRNA stability in renal cell carcinoma. Oncogene, 2005. 24(53): pp. 7850-8.
54. Hergovich, A., et al., Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nat Cell Biol, 2003. 5(1): pp. 64-70.
55. Knauth, K., et al., Renal cell carcinoma risk in type 2 von Hippel-Lindau disease correlates with defects in pVHL stability and HIF-1alpha interactions. Oncogene, 2006. 25(3): pp. 370-7.
56. Clifford, S., et al., Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum Mol Genet, 2001. 10: pp. 1029-38.
57. Mandriota, S. J., et al., HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell, 2002. 1(5): pp. 459-68.
58. Zhuang, Z., et al., A microscopic dissection technique for archival DNA analysis of specific cell populations in lesions <1 mm in size. Am J Pathol, 1995. 146: pp. 620-5.
59. Zhuang, Z., et al., Detection of von Hippel-Lindau disease gene mutations in paraffin-embedded sporadic renal cell carcinoma specimens. Mod Pathol, 1996. 9(8): pp. 838-42.
60. Lubensky, I. A., et al., Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. Am J Pathol, 1996. 149: pp. 2089-94.
61. Lieubeau-Teillet, B., et al., von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids. Cancer Res., 1998. 58: pp. 4957-62.
62. Pause, A., et al., The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Proc Natl Acad Sci USA, 1998. 95: pp. 993-8.
63. Kamada, M., et al., von Hippel-Lindau protein promotes the assembly of actin and vinculin and inhibits cell motility. Cancer Res, 2001. 61(10): pp. 4184-9.
64. Potter, C. and A. L. Harris, Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle, 2004. 3(2): pp. 164-7.
65. An, J. and M. B. Rettig, Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity. Mol Cell Biol, 2005. 25(17): pp. 7546-56.
66. Yao, M., et al., VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst, 2002. 94(20): pp. 1569-75.
67. Maxwell, P., et al., The von Hippel-Lindau gene product is necessary for oxygen-dependent proteolysis of hypoxia-inducible factor a subunits. Nature, 1999. 399: pp. 271-5.
68. Kondo, K., et al., Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol, 2003. 1(3): pp. E83.
69. Kondo, K., et al., Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell, 2002. 1(3): pp. 237-46.
70. Maranchie, J. K., et al., The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell, 2002. 1(3): pp. 247-55.
71. Zimmer, M., et al., Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/-tumors. Mol Cancer Res, 2004. 2(2): pp. 89-95.
72. Arsham, A. M., J. J. Howell, and M. C. Simon, A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. J Biol Chem, 2003. 278(32): pp. 29655-60.
73. Brugarolas, J. B., et al., TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell, 2003. 4(2): pp. 147-58.
74. Hudson, C. C., et al., Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol, 2002. 22(20): pp. 7004-14.
75. Brugarolas, J., et al., Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev, 2004. 18(23): pp. 2893-904.
76. Isaacs, J. S., et al., Hsp90 regulates a von Hippel-Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem, 2002. 277(33): pp. 29936-44.
77. Minet, E., et al., Hypoxia-induced activation of HIF-1: role of HIF-1alpha-Hsp90 interaction. FEBS Lett, 1999. 460(2): pp. 251-6.
78. Mabjeesh, N. J., et al., Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res, 2002. 62(9): pp. 2478-82.
79. Hur, E., et al., Reduction of hypoxia-induced transcription through the repression of hypoxiainducible factor-1alpha/aryl hydrocarbon receptor nuclear translocator DNA binding by the 90-kDa heat-shock protein inhibitor radicicol. Mol Pharmacol, 2002. 62(5): pp. 975-82.
80. Thomas, G. V., et al., Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med, 2006. 12(1): pp. 122-7.
81. Kim, M. S., et al., Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med, 2001. 7(4): pp. 437-43.
82. Kong, X., et al., aHistone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1{alpha}. Mol Cell Biol, 2006. 26(6): pp. 2019-28.
83. Atadja, P., et al., Molecular and cellular basis for the anti-proliferative effects of the HDAC inhibitor LAQ824. Novartis Found Symp, 2004. 259: pp. 249-66; discussion 266-8, 285-8.
84. Bali, P., et al., Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem, 2005. 280(29): pp. 26729-34.
85. Neckers, L., Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med, 2002. 8(4 Suppl): pp. S55-S61.
86. Neckers, L. and K. Neckers, Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics - an update. Expert Opin Emerg Drugs, 2005. 10(1): pp. 137-49.
87. Welsh, S. J., et al., The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Mol Cancer Ther, 2003. 2(3): pp. 235-43.
88. Welsh, S., et al., Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol Cancer Ther, 2004. 3(3): pp. 233-44.
89. Rapisarda, A., et al., Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res, 2002. 62(15): pp. 4316-24.
90. Rapisarda, A., et al., Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res, 2004. 64(4): pp. 1475-82.
91. Mabjeesh, N. J., et al., 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell, 2003. 3(4): pp. 363-75.
92. Benjamin, L. E., et al., Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Investig, 1999. 103(2): pp. 159-65.
93. Bergers, G., et al., Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Investig, 2003. 111(9): pp. 1287-95.
94. Bergers, G., et al., Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol, 2000. 2(10): pp. 737-44.
95. De Paulsen, N., et al., Role of transforming growth factor-alpha in VHL-/-clear cell renal carcinoma cell proliferation: a possible mechanism coupling von Hippel-Lindau tumor suppressor inactivation and tumorigenesis. Proc Natl Acad Sci USA, 2001. 13: pp. 1387-92.
96. Smith, K., et al., Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/-renal cancer. Cancer Res, 2005. 65(12): pp. 5221-30.
97. Staller, P., et al., Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature, 2003. 425(6955): pp. 307-11.
98. Zagzag, D., et al., Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor. Cancer Res, 2005. 65(14): pp. 6178-88.
99. Bindra, R. S., et al., VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. Cancer Res, 2002. 62(11): pp. 3014-9.
100. Raval, R. R., et al., Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol, 2005. 25(13): pp. 5675-86.
101. Sellers, W. R. and W. G. Kaelin, Role of the retinoblastoma protein in the pathogenesis of human cancer. J Clin Oncol, 1997. 15: pp. 3301-12.
102. Wulf, G., et al., Modeling breast cancer in vivo and ex vivo reveals an essential role of Pin1 in tumorigenesis. EMBO J, 2004. 23(16): pp. 3397-407.
103. Ferrara N., et al., The biology of VEGF and its receptors Nat Med 2003. 9(6): pp. 669-76.
104. Warren, R. S., et al., Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Investig, 1995. 95: pp. 1789-97.
105. Yang, J. C., et al., A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med, 2003. 349(5): pp. 427-34.
106. Rini, B. I., et al., Cancer and Leukemia Group B 90206: a randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res, 2004. 10: pp. 2584-6.
107. Hainsworth, J. D., et al., Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol, 2005. 23: pp. 7889-96.
108. Bukowski, R. M., et al., OBevacizumab with or without erlotinib in metastatic renal cell carcinoma. Proc Am Soc Clin Oncol, 2006. 24(18S): abstr. 4523.
109. Drucer, B. J., et al., Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New Engl J Med, 2001. 344(14): pp. 1031-7.
110. Demetri, G. D., et al., Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. J Clin Oncol, 2004. 22(13): pp. 2532-9.
111. Motzer, R. J., et al., Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol, 2006. 24(1): pp. 16-24.
112. Motzer, R. J., et al., Sunitinib in patients with metastatic renal cell carcinoma. JAMA, 2006. 295: pp. 2516-24.
113. Ratain, M. J., et al., Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (Bay 43-9006) in patients with advanced renal cell carcinoma. Proc Am Soc Clin Oncol, 2005. 23(16S): abstr. 4544.
114. Rini, B. I., et al., aAG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). Proc Am Soc Clin Oncol, 2005. 23(16 S): abstr. 4509.
115. George, D. J., et al., Phase I study of PTK787/ZK 222584 (PTK/ZK) in metastatic renal cell carcinoma. Proc Am Soc Clin Oncol, 2003. 22: abstr. 1548.
116. Dawson, N., et al., A phase II trial of ZD1839 in stage IV and recurrent renal cell carcinoma. Proc Am Soc Clin Oncol, 2003. 22: abstr. 1623.
117. Jermann, M. J. M., et al., An open-label phase II trial to evaluate the efficacy and safety of gefitinib in patients with locally advanced, relapsed or metastatic renal cell cancer. Proc Am Soc Clin Oncol, 2003. 22: abstr. 1681.
118. Vuky, J. F. M., et al., Phase II trial of imatinib mesylate (formerly known as STI-571) in patients with metastatic renal cell carcinoma (RCC). Proc Am Soc Clin Oncol, 2003. 22: abstr. 1687.
119. Motzer, R. J., et al., Phase 3 randomized trial of sunitinib malate (SU11248) versus interferon-alfa as first-line systemic therapy for patients with metastatic renal cell carcinoma. Proc Am Soc Clin Oncol, 2006. 24(18S): abstr. 3.
120. Escudier, B, et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol, 2005. 23(16S): abstr. 4510.
121. Potapova, O., et al., Mechanism of action and biomarker studies of SU11248, a selective inhibitor of split kinase domain receptor tyrosine kinases (including VEGF receptors, PDGF receptors, c-Kit and Flt3). Eur J Cancer, 2002. 38(s 7): pp. 194-200.
122. Mendel, D. B., et al., In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res, 2003. 9: pp. 327-37.
123. Abrams, T. J., et al., SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther, 2003. 2:471-8.
124. Fiedler, W., et al., A phase I study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood, 2005. 105: pp. 986-93.
125. Faivre, S., et al., Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol, 2006. 24: pp. 25-35.
126. Atkins, M. B., et al., Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol, 2004. 22(5): pp. 909-18.
127. Hudes, G., et al., A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferonalpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma. Proc Am Soc Clin Oncol, 2006. 24(18S): abstr. 4.
128. Eisen, T, et al., Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): impact of crossover on survival. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: pp. 4524.